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Abstract
Introduction: Stimulant medication improves hyperactivity, inattention, and impulsivity in both pediatric and adult
populations with Attention Deficit Hyperactivity Disorder (ADHD). However, data regarding the optimal dosage in
adults is still limited.
Case presentation: We report the case of a 38-year-old Caucasian patient who was diagnosed with Attention
Deficit Hyperactivity Disorder when he was nine years old. He then received up to 10 mg methylphenidate
(RitalinW) and 20 mg sustained-release methylphenidate (Ritalin SRW) daily. When he was 13, his medication was
changed to desipramine (NorpraminW), and both RitalinW and Ritalin SRW were discontinued; and at age 18, when
he developed obsessive-compulsive symptoms, his medication was changed to clomipramine (AnafranilW) 75 mg
daily. Still suffering from inattention and hyperactivity, the patient began college when he was 19, but did not
receive stimulant medication until three years later, when RitalinW 60 mg daily was re-established. During the 14
months that followed, he began to use RitalinW excessively, both orally and rectally, in dosages from 4800-6000 mg
daily. Four years ago, he was referred to our outpatient service, where his Attention Deficit Hyperactivity Disorder
was re-evaluated. At that point, the patient’s daily RitalinW dosage was reduced to 200 mg daily orally, but he still
experienced pronounced symptoms of, Attention Deficit Hyperactivity Disorder so this dosage was raised again.
The patient’s plasma levels consistently remained between 60–187 nmol/l—within the recommended range—and
signs of his obsessive-compulsive symptoms diminished with fluoxetine 40 mg daily. Finally, on a dosage of 378
mg extended-release methylphenidate (ConcertaW), his symptoms of Attention Deficit Hyperactivity Disorder have
improved dramatically and no further use of methylphenidate has been recorded during the 24 months preceding
this report.
Conclusions: Symptoms of Attention Deficit Hyperactivity Disorder (ADHD) in this adult patient, who also
manifested a co-occurring obsessive compulsive disorder, dramatically improved only after application of a
higher-than-normal dose of methylphenidate. We therefore suggest that clinicians consider these findings in
relation to their adherence to current therapeutic guidelines.
Introduction
Attention Deficit Hyperactivity Disorder (ADHD) is a
prevalent mental disorder characterized by symptoms of in-
attention (distractibility), hyperactivity, and impulsivity—all
of which contribute to significant psychosocial impairment
in the affected individuals [1]. Previously believed to be
solely a disorder of childhood and adolescence, it is now
accepted that about two-thirds of children diagnosed with
ADHD will experience its symptoms in adulthood [2,3].
For example, adults suffering from ADHD are less fre-
quently employed on a fulltime basis, have difficulty main-
taining personal relationships, and are generally less
satisfied with their families and their social and professional
lives [4].
Prevalence of adult ADHD in the United States is esti-
mated at around 4.4%, and the disorder is highly co-morbid
with many other DSM IV disorders [1,5,6]. Although
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clinicians widely agree that a treatment approach which
combines psychotherapeutic and pharmacological interven-
tions is optimal, the prescription of stimulant medication is
clearly the first line of treatment and is known to improve
symptoms in both pediatric and adult populations [7]. In
particular, the use of methylphenidate (MPH), has proved
an efficacious pharmacological treatment for adult ADHD
when administered in weight-adjusted doses equivalent to
those used in a pediatric population [8].
Although the mechanism that underlies the action of
stimulants in adult ADHD is still being investigated, the
efficacy of both amphetamines and MPH is attributed to
their ability to increase striatal and cortical dopamine
levels [9]. While both drugs share common mechanisms
of action, amphetamines increase dopamine release,
whereas MPH inhibits re-uptake of dopamine by block-
ing the dopamine transporter (DAT) [9,10].
Oral formulations of MPH are available in short- and
intermediate-acting preparations, as well as slow-release
and long-acting ones. Oral administration of immediate-
release MPH reaches peak plasma concentration after
two hours, and decreases thereafter [5].
As a consequence, immediate-release MPH must be
taken several times a day—and, even so, spikes in plasma
level occur. On the other hand, long-acting formula-
tions, such as once-daily osmotic release oral system
(OROS) MPH (ConcertaW), improve patient compliance
and demonstrate efficacy similar to that of an
immediate-release dose of MPH three times daily [11].
Data on the optimal dosage of these stimulants in adults
is still limited, with upper-limit recommendations usu-
ally being 1 mg/kg for methylphenidate and 0.5 mg/kg
for dexamphetamine [8].
Case presentation
We report the case of a 38-year-old Caucasian man, with
dual citizenship in the USA and Switzerland, who has
been in treatment at the outpatient service of the Psychi-
atric University Hospital for the last four years. During
childhood and adolescence, his family frequently relo-
cated from Switzerland to the USA, and vice versa. His
father, an entrepreneur, described the patient as being an
“uneasy” child who was different from his siblings, and
he had sought professional help for his son from a child
psychiatrist in the USA. This psychiatrist diagnosed the
patient, who was then nine years old, with ADHD, and
over the course of the next five years, the patient
received up to 10 mg of immediate-release MPH (Rita-
linW). Later on, his dosage was increased to 20 mg of
sustained-release MPH (Ritalin SRW) daily, which ini-
tially improved the patient’s symptoms of hyperactivity
and inattention.
Twenty-five years ago, while he was still living in the
USA, the patient’s medication was changed—for the
same indication—to desipramine (NorpraminW), and
MPH (RitalinW) was discontinued. Nevertheless, most of
his difficulties persisted throughout elementary- and
middle school. Between ages 14 and 16, the patient was
therefore sent to a school that specialized in the instruc-
tion of students with learning disabilities such as dys-
lexia. At age 18, he developed obsessive-compulsive
traits and received counselling; his medication was also
changed at that time to clomipramine (AnafranilW)
75 mg/daily.
Soon afterward, the family again relocated from the
USA to Switzerland, where the patient attended high
school—followed, in 1993, by college in the USA. Still
suffering from symptoms of inattention and hyperactiv-
ity, he did not finish his studies at this college, and failed
in several other attempts to obtain a secondary degree in
the USA, Great Britain, and Switzerland. The patient
recalled that he never seemed able to “focus.”
For unknown reasons, he did not receive further
stimulant medication until six years ago, when a Swiss
psychiatrist prescribed immediate-release MPH (Rita-
linW) 60 mg/daily to reduce the patient’s distractibility at
his newfound job as a sales clerk. The patient experi-
enced MPH as highly effective, but not sustainable
throughout the course of a day. During the following
14 months, he therefore began to use RitalinW exces-
sively, both orally and rectally, in dosages up to 4800-
6000 mg/daily, by applying to thirty different doctors in
three different cantons of Switzerland. He thereby ful-
filled the criteria for stimulant dependence, although he
never used any substance other than MPH.
Four years ago, the patient was referred to our out-
patient service for treatment. He received clinical diag-
nostic interviewing (SCID I, SCID II) and his ADHD
was re-evaluated using recommended practice para-
meters [12]. In addition, his plasma levels of methyl-
phenidate were obtained, a routine medical workup was
performed, and information on his past medical history
was collected.
Physical examination revealed chronic back pain, and
a local rheumatologist diagnosed ankylosing spondylitis
(Bekhterev's disease). No other pathology was found, nor
did the patient have any history of palpitations, tachycar-
dia and dyspnea, or other adverse cardiovascular effects
commonly associated with stimulant use. His blood
pressure and heart rate were within the normal range,
and an ECG showed no abnormalities.
The diagnostic (SCID) testing confirmed the presence
of an obsessive-compulsive disorder and revealed a com-
bined personality disorder. There was no further history
of substance misuse or dependency; the patient reported
only a recreational use of cannabis. The patient first
received immediate-release MPH 200 mg. This was later
changed to 240 mg, and finally to 270 mg MPH per day.
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We repeatedly checked the plasma levels of MPH in the
blood under all these dosages and found them to be
within the reference range. Moreover, when the patient
received extended-release MPH at a dosage of 378 mg/
day, his blood plasma remained within reference range.
The reference range is 43-257 nmol, and we found his
plasma levels to be between 60 nmol-187 nmol/l.
Using a combined psychosocial (CBT) and pharma-
cotherapeutic treatment approach, the patient’s daily
RitalinW dosage could initially be reduced to 200 mg/
daily orally. However, the patient still experienced pro-
nounced symptoms of ADHD at this dosage, and these
symptoms were also reported by his family members. He
exhibited high levels of distractibility both within the
clinical setting (e.g., during group therapy), and at home,
where he was unable to help around the house or con-
tribute to the care of his newborn child.
While his signs of OCD diminished with fluoxetine
40 mg/daily, his ADHD symptoms only improved dra-
matically after his dosage was increased to 378 mg of
extended-release MPH (ConcertaW). This was reflected
in an increase of his score on the Global Assessment of
Functioning scale from 43 to 68; and at home, the pa-
tient was able to care for his child several days a week
and re-establish interpersonal relationships. No further
excessive use of methylphenidate has been recorded for
the past 24 months.
Discussion
According to the NHS National Institute for Health and
Clinical Excellence (NICE) 2008 guidelines for treatment
of adult ADHD, MPH dosage should be increased grad-
ually until further improvement of ADHD symptoms
ceases (e.g., symptom reduction, behavior change,
improvements in education and/or relationships) [13].
These same guidelines set the maximum dose at 100 mg
MPH/day.
Since we had seen improvement in our patient only at a
higher-than-recommended dosage, we not only monitored
for side effects (e.g., manic symptoms, psychosis, and sui-
cidal ideation), all of which were non-existent—we also
obtained the patient’s plasma levels of methylphenidate.
After the addition of deuterated methylphenidate as an in-
ternal standard, methylphenidate was obtained from serum
samples by liquid-liquid extraction, and was subsequently
measured by chromatographic separation on C18 reversed-
phase HPLC columns (Interchim, France) and electrospray
ionisation mass spectrometry [14].
Using Positron Emission Tomography (PET) examin-
ation, Swanson et al. demonstrated a high correlation
between peak plasma concentration of the d-isomer of
methylphenidate (d-MPH) and dopamine transporter
occupancy, and concluded that plasma concentration of
d-MPH served as a good measure of brain levels of
methylphenidate [15]. The same authors estimated that
the dose required to block 50% of the DAT in adults was
0.25 mg/kg.
Since our patient had been prescribed the racemic
mixture of MPH (1:1 ratio for d:I enantiomers), we were
only able to obtain and evaluate d,I-MPH plasma levels
– all of which were within reference range: 43 –
257 nmol/l (d,I-MPH). To compare our results with the
findings of Swanson et al., we therefore calculated d-
MPH plasma levels, which indicated that our patient’s
brain levels of methylphenidate were probably also
within the norm.
Unlike many other substances, which are metabolized
by hepatic cytochrome P450 (CYP) enzymes, MPH is
converted to inactive ritalinic acid by carboxylesterase
(CES). Liver carboxylesterase 1 (CES1) is responsible for
the hydrolysis of both d- and l-isomers of MPH,includ-
ing the first-pass metabolism of this substance [16]. Al-
though there is evidence that specific CES1 gene
variants may exist, which could lead to clinically signifi-
cant alterations in pharmacokinetics and drug response
of carboxylesterase 1 substrates, only two CES1 variants
have been identified to our knowledge, both of which re-
sult in reduced enzyme activity [17,18]. Furthermore, the
presence of one or two of these variants would not ex-
plain our findings, since their presence would result in
higher plasma levels of MPH, not lower ones. While we
cannot rule out the possibility this patient possesses a
CES1 gene variant with an increased enzyme activity, no
genetic testing is currently available to confirm or dis-
confirm this assumption.
An illusory positive bias has been reported on the part
of both children and adults with ADHD, suggesting that
patients with ADHD are not the most reliable source of
their own psychosocial functioning [3]. We therefore re-
lied primarily on physician ratings and family reports to
determine our patient’s response to MPH, and relied
only secondarily on his self-rating.
It is now widely accepted that the use of methylphen-
idate within recommended dose-ranges offers a safe
form of treatment despite possible increases in patients’
heart rate and blood pressure. In fact, a recent retro-
spective, population-based cohort study by Habel et al.,
on a total of 150,359 young and middle-aged adults with
a current or new use of ADHD medication, did not find
an increased risk of serious cardiovascular events [19].
However, since cases of sudden cardiac death have been
reported when prescribing methylphenidate in combin-
ation with other drugs (e.g., clonidine) [20], we closely
monitored for adverse cardiovascular effects, paying spe-
cial attention to potential increases in blood pressure
and heart rate. Despite the high dose of MPH that this
patient received, we found no significant changes in
these parameters.
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Results of an earlier study in mice suggest that beta 2-
adrenergic agonist drugs are capable of potentiating
methylphenidate-induced hepatotoxicity by increasing
hepatic methylphenidate concentrations [21]. However,
we found only one case report, from 1972, in which hep-
atotoxicity was associated with use of methylphenidate
[22], and we found no elevated liver enzymes in our pa-
tient during his treatment.
Because of its potential for misuse, some clinicians dis-
courage use of methylphenidate in ADHD patients with a
co-occurring substance use disorder (SUD). However, ana-
lyses from two randomized placebo-controlled trials
among adolescents with a SUD concluded that extended-
release MPH can be safely administered, despite non-
abstinence, when it is closely monitored [23].
Data were not available to us on the use of high doses
of MPH especially among the elderly or those patients
with co-morbid heart or liver conditions. But data that
stem primarily from poison centers show that the most
common symptoms in patients with methylphenidate
abuse were tachycardia, agitation/irritability, and hyper-
tension. Outcomes were reported to be good, especially
in cases only involving methylphenidate abuse [24].
Moreover, a recent Swiss study of 14 patients with self-
reported MPH abuse of 30-400 mg MPH found that oral
or nasal MPH abuse was associated with only minor to
moderate sympathomimetic toxicity, which was generally
self-limited and sometimes treated with sedatives [25].
And the case study of a 14-year-old girl who had ingested
21 long-acting methylphenidate 54-mg tablets (1,134 mg
ConcertaW) described a sympathomimetic syndrome with
agitation, visual hallucinations, slight hypertension, and
sinus tachycardia, but no life-threatening symptoms [26].
We did not observe any such symptoms in our patient.
Conclusions
In this adult patient, who has ADHD, an obsessive-
compulsive disorder, and a combined personality dis-
order, we observed an excessive use of methylphenidate,
which fulfilled the criteria of dependence at the time of
his admission to our outpatient services. Clinically, we
observed dramatic improvement of his ADHD symp-
toms only after application of a higher-than-normal dose
of MPH.
To our knowledge, this is the first reported case of
high-dose treatment in a patient with adult ADHD. We
therefore suggest that clinicians consider these findings
in their work with patients when ADHD symptoms do
not improve sufficiently with currently recommended
dosages of stimulants. Because no long-term experiences
with high-dose methylphenidate treatment have been
published to date, we further advise clinicians to moni-
tor clinical symptoms when using high doses of MPH,
despite the fact that we did not find a sympathomimetic
syndrome.
Patient’s perspective
“As a child, I was always getting into trouble for 'having
too much energy.' I never understood why people were
always moving slowly. My parents and teachers were so
frustrated with me that I couldn't organize myself or
learn things at the same pace as 'everyone else.’ It was
decided that I would try Ritalin, but it never lasted long
enough to make that much of an improvement and I
stopped taking it.
As an adult, the demands from my relationships be-
came more intense, as did everyone's frustrations, in-
cluding my own. The pressure to try and solve my focus
problems and impulsive behaviors became so great that
my family encouraged me to try an ADHD medicine
again. I was prescribed a 'normal' dose of Concerta, and
it felt like a light bulb had been turned on in my head.
Suddenly I was able to concentrate long enough to read,
began keeping appointments and coping better with day
to day activities. Caring for our son became more man-
ageable as I was able to plan and organize his day with-
out becoming totally overwhelmed.
But soon after I started the medicine, I noticed the
positive focus wore off so quickly between doses that I
felt I required a higher dose in order to maintain focus
for the entire day. It was difficult for me to explain this
need to the medical community as it was something that
was out of the ordinary apparently. All I knew was that
it just 'wore off too quickly.’ Under close observation the
dosage was increased, eventually to 7 tablets a day.
Through blood work it was proven that my body was
processing the medicine at a normal level.
Although I still experience focus issues from ADHD,
the higher dosage of the medicine has been an aid in
helping me manage and cope with those disabilities.”
Consent
Written, informed consent was obtained from the pa-
tient for publication of this case report and accompany-
ing graphs. A copy of this consent is available for review
by the Editor-in-Chief of this journal.
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